A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors
Phase of Trial: Phase I/II
Latest Information Update: 28 Mar 2018
At a glance
- Drugs INCAGN 1876 (Primary)
- Indications Endometrial cancer; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Incyte Corporation
- 22 Jun 2016 According to an Agenus Inc. media release, the first patient has been dosed in this trial.
- 20 Jun 2016 Status changed from not yet recruiting to recruiting.
- 02 Mar 2016 Status changed from planning to not yet recruiting as reported by ClinicalTrials.gov.